InDex Pharmaceuticals updates shareholders list
October 28, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that the list of shareholders has been updated on the homepage with information as of October 18, 2019.
The 15 largest shareholders in InDex Pharmaceuticals Holding AB (publ) were per October 18, 2019:
| Shareholder | Number of shares | Ownership % | Votes % |
| SEB Venture Capital | 12 994 367 | 14.6 | 14.6 |
| Stiftelsen Industrifonden | 12 865 296 | 14.5 | 14.5 |
| Linc AB | 8 875 650 | 10.0 | 10.0 |
| Fjärde AP-fonden | 6 400 000 | 7.2 | 7.2 |
| Avanza Pension | 3 338 907 | 3.8 | 3.8 |
| Staffan Rasjö | 3 124 718 | 3.5 | 3.5 |
| Originat AB | 2 700 000 | 3.0 | 3.0 |
| SEB Life International | 2 321 225 | 2.6 | 2.6 |
| Skandinaviska Enskilda Banken SA | 2 300 000 | 2.6 | 2.6 |
| Nordnet Pensionsförsäkring AB | 2 001 604 | 2.3 | 2.3 |
| SEB Stiftelsen | 1 785 714 | 2.0 | 2.0 |
| Ponderus Invest AB | 1 000 000 | 1.1 | 1.1 |
| Rune Pettersson | 980 081 | 1.1 | 1.1 |
| ABN AMRO Global Custody Services NV | 913 955 | 1.0 | 1.0 |
| Ålandsbanken | 891 735 | 1.0 | 1.0 |
For more information:
Peter Zerhouni, CEO
Phone: +46 8 508 847 35
E-mail: peter.zerhouni@indexpharma.com
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm. Redeye AB with e-mail certifiedadviser@redeye.se and phone number +46 8 121 576 90 is the company’s Certified Adviser. For more information, please visit www.indexpharma.com
Publication
The information was submitted for publication through the agency of the contact person set out above at 08:00 CET on October 28, 2019.